D0368 - Characteristics, Medication and Healthcare Utilization of Crohn’s Disease Patients Stratified by Short-CDAI Status: Descriptive Results From the IBD PLEXUS and IQVIA Linked Dataset

Mirko Sikirica, PharmD¹, Kirsten Lum, PhD², Feifei Yang, MD, MS³, Matthew Molaei, PharmD³, Yihan Zhao, PhD^2
1Janssen Global Services, LLC, Horsham, PA; ²Janssen Business Technology Commercial Data Sciences, Titusville, NJ; ³Janssen Scientific Affairs, LLC, Horsham, PA

Introduction: Crohn’s disease (CD) is a life-long chronic inflammatory disorder. CD studies in real-world settings usually do not include disease severity measures since few longitudinal databases with robust clinical data and long-term administrative claims exist. We describe the demographics, clinical characteristics, medications and healthcare utilization of patients with CD stratified by the short Crohn's Disease Activity Index (sCDAI) with a unique CCF and IQVIA linked dataset.

Methods: This retrospective analysis used data from the Crohn’s & Colitis Foundation (CCF) SPARC IBD and IBD QORUS data linked with IQVIA’s prescription and medical claims (LRx/Dx), to identify a cohort of CD patients with up to 24 months pre-enrollment and at least 18 months of follow-up. Enrollment date into CCF studies was used as the Index date and CD patients were stratified into three disease activity cohorts based on enrollment sCDAI scores: Remitters (R) sCDAI < 150, Non-remitters and non-moderate-severe (nRnMS, a.k.a. ‘Mild’) sCDAI = 150-219, and Moderate-Severe (MS) sCDAI ≥220. Medication use for biologics, immunomodulators and 5-ASAs was based on a hierarchy of highest step achieved. Descriptive analyses were performed for baseline period clinical characteristics, medications and healthcare utilization.

Results: Of the 1756 CD patients included, 1027 were in R, 361 were nRnMS and 368 were in MS disease activity. Mean age for the three groups was around 43 years. Time since CD diagnosis was more than 10yrs in 54.5%, 52.9% and 58.4% of the R, nRnMS and MS groups, respectively. Mean (±SD) sCDAI scores at enrollment were 96.2 (±28.1) for R, 182.0 (±20.3) for nRnMS and 302.0 (±77.7) for the MS group. Biologics were used in 37.5% of R, 39.3% of nRnMS and 33.4% of MS patients. High use of corticosteroids and opioids was seen across all three groups. Emergency room visits increased across the R (7.1%), nRnMS (12.2%) and MS (27.2%) cohorts. Hospitalizations were highest in the MS group. (Table 1)

Discussion: We utilized a unique longitudinal dataset linked to administrative claims, to provide an initial description of characteristics between three severity-based CD cohorts. We observed generally more severe disease features, medication and healthcare utilization in CD patients who were not in remission. Future research will evaluate relationships between disease characteristics, treatment patterns and poor outcomes during follow-up.



Disclosures:


Mirko Sikirica, PharmD¹, Kirsten Lum, PhD², Feifei Yang, MD, MS³, Matthew Molaei, PharmD³, Yihan Zhao, PhD². D0368 - Characteristics, Medication and Healthcare Utilization of Crohn’s Disease Patients Stratified by Short-CDAI Status: Descriptive Results From the IBD PLEXUS and IQVIA Linked Dataset, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.